SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure

Published: 31 August 2022

Views:
51750
Likes:
7

Views:
51750
Likes:
7
Share:

Now Playing
Part 3
Practical Considerations for Treating HF With Mildly Reduced and preserved EF
Carolyn Lam

Up Next

11m 29s

Part 4 Implementing Best Practices Across the Spectrum of Heart Failure
Muthiah Vaduganathan

12m 17s

Part 5 Q&A and Discussion
Scott Solomon, John JV McMurray, Carolyn Lam, Muthiah Vaduganathan

18m 8s

Part 1 SGLT2 Inhibitors: Light at the End of the Tunnel Scott Solomon, John JV McMurray, Carolyn Lam, Muthiah Vaduganathan

9m 53s

Part 2 SGLT2 Inhibitors Across the Spectrum of Heart Failure John JV McMurray

Average (ratings)

No ratings

Your rating

Overview

During this unique broadcast, ‘SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure’, Radcliffe Medical Education brings together a globally-renowned faculty to participate in a discussion centred around the presentation of the latest SGLT-2 inhibition data and how this translates to the treatment of Heart Failure patients.

Presented, and recorded, at ESC Congress 2022 in Barcelona, this programme is now available to watch on-demand. The programme is chaired by Prof Scott Solomon (Boston, US), who is joined by Prof John McMurray (Glasgow, UK), Prof Carolyn Lam (Singapore, SG) and Dr Muthiah Vaduganathan (Boston, US) while they explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.

This satellite symposium is supported by an unrestricted educational grant from AstraZeneca who had no involvement in the creation of the content.

CME accredited version available here

This satellite symposium is supported by an unrestricted educational grant from AstraZeneca who had no involvement in the creation of the content.

Learning Objectives

Upon participation in this programme, physicians will be able to:

Recall the results of key trials in HFmrEF in different patients' sub-groups
Describe how SGLT-2 inhibitors can be used across the range of LVEF
Apply emerging diagnostic approaches for HFpEF and HFmrEF
Implement best-practice strategies across the range of LVEF

This programme is intended to educate:

Global cardiologists
Heart Failure specialists
Primary care physicians
Nurses
Pharmacists

More from this programme

Part 1

SGLT2 Inhibitors - Another piece of the Puzzle in Heart Failure

1 session
SGLT2 Inhibitors: Light at the End of the Tunnel	Watch now

Part 2

SGLT2 Inhibitors Across the Spectrum of Heart Failure

1 session
SGLT2 Inhibitors Across the Spectrum of Heart Failure	Watch now

Part 3

Practical Considerations for Treating HF With Mildly Reduced and Preserved EP

1 session
Practical Considerations for Treating HF With Mildly Reduced and preserved EF	Watch now

Part 4

Implementing Best Practices Across the Spectrum of Heart Failure

1 session
Implementing Best Practices Across the Spectrum of Heart Failure	Watch now

Part 5

Q&A and Discussion

1 session
Q&A and Discussion	Watch now

Faculty Biographies

Carolyn Lam

Professor and Senior Consultant

Prof Carolyn Lam is a Senior Consultant at the Department of Cardiology and Director of Women's Heart Health at the National Heart Centre Singapore, having pioneered the first Women’s Heart Clinic in Singapore. Prof Lam is a world-renowned specialist in heart failure (particularly heart failure with preserved ejection fraction [HFpEF]). Her work in the PARAGON-HF and EMPEROR-Preserved trials led to the first FDA-approved treatment for HFpEF and the first robustly positive clinical outcomes trial in HFpEF to-date.

View full profile